Radiomics offers improved assessment of spinal cord pathology in MS, surpassing conventional MRI in precision and sensitivity. A study identified 12 significant radiomic features, with four ...
NervGen is a Canadian early-stage biotech company with unprecedented preclinical work in spinal cord injury and multiple sclerosis. The company is finalizing a Phase 1 clinical trial for its ‘pipeline ...
MedPage Today brought together three expert leaders for a virtual roundtable discussion on the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and ...
Sex (ref men) Women 1.42 0.99; 2.05 0.1 Initial course of MS (ref primary progressive) Remitting-relapsing 0.20 0.13; 0.31 0.0001 Incomplete recovery from the first relapse (ref yes) No 1.10 0.69; ...
Please provide your email address to receive an email when new articles are posted on . Fenebrutinib is a highly selective, noncovalent, reversible Bruton’s tyrose kinase inhibitor. Treatment with ...
—In a new study, the extent of microstructural damage in patients with early relapsing-remitting multiple sclerosis (RRMS) was associated with worse disability and spinal cord atrophy at 5 years. Here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results